Clinical Trials Using CD40 Agonistic Monoclonal Antibody APX005M

Clinical trials are research studies that involve people. The clinical trials on this list are studying CD40 Agonistic Monoclonal Antibody APX005M. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

    The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.
    Location: 7 locations

  • CD40 Agonistic Antibody APX005M in Combination With Nivolumab

    This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.
    Location: 7 locations

  • APX005M and Doxorubicin in Treating Patients with Advanced Soft Tissue Sarcoma

    This phase II trial studies how well APX005M works when given together with standard of care doxorubicin in treating patients with soft tissue sarcoma that has spread to other places in the body (advanced). Immunotherapy with APX005M, may induce changes in the body’s immune system, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving APX005M and doxorubicin may work better in treating patients with soft tissue sarcoma.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • APX005M, Nivolumab, and Cabiralizumab in Treating Patients with Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Cancer Who Have Progressed on Anti-PD1 / PDL-1 Therapy

    This phase I / Ib trial studies the best dose and side effects of APX005M, and how well it works in combination with nivolumab and cabiralizumab in treating patients with melanoma, non-small cell lung cancer and renal cell cancer that have spread to other places in the body and have progressed on anti-PD -1 / PD-L 1 therapy. Monoclonal antibodies, such as APX005M, nivolumab and cabiralizumab, interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • APX005M, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Esophageal Cancer or Gastroesophageal Junction Cancer that Can Be Removed by Surgery

    This pilot phase II trial studies the side effects of CD40 agonistic monoclonal antibody APX005M (APX005M), chemotherapy, and radiation therapy, and to see how well they work when given before surgery in treating patients with esophageal cancer or gastroesophageal cancer that can be removed by surgery. APX005M is intended to stimulate the body’s own immune system so that the immune cells can more effectively invade and destroy the tumor, adding to the benefits of the chemotherapy and radiation therapy. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving APX005M, chemotherapy, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • CD40 Agonistic Monoclonal Antibody APX005M and Pembrolizumab in Treating Patients with Stage III-IV Melanoma

    This phase I / II trial studies the side effects and best dose of CD40 agonistic monoclonal antibody APX005M when given together with pembrolizumab and to see how well it works in treating patients with stage III-IV melanoma. Monoclonal antibodies, such as CD40 agonistic monoclonal antibody APX005M and pembrolizumab, may block tumor growth in different ways by targeting certain cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • CD40 Agonistic Monoclonal Antibody APX005M in Treating Pediatric Patients with Recurrent or Refractory Brain Tumors

    This phase I trial studies the side effects and best dose of CD40 agonistic monoclonal antibody APX005M in treating pediatric patients with brain tumors that have come back or do not respond to treatment. Immunotherapy with CD40 agonistic monoclonal antibody APX005M, may induce changes in the body’s immune system, and may interfere with the ability of tumor cells to grow and spread.
    Location: 11 locations